Morgan Stanley Cuts Revolution Medicines Price Target to $247 From $272
Morgan Stanley has lowered its price target on Revolution Medicines shares to $247 per share from $272, according to Dow Jones Newswires.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Morgan Stanley reduced its price target on Revolution Medicines (RVMD) shares to $247 per share from the previously set $272. Dow Jones Newswires reports the change, citing ratings data from Benzinga.
The item concerns an analyst rating action rather than any decision made by the company itself.
why it matters
A price target revision is a routine event that reflects one bank's view of a specific stock. It has limited impact on the share price and the wider sector, so its significance for most investors is modest.
tags
instruments
sources
- Revolution Medicines Price Target Cut to $247.00/Share From $272.00 by Morgan Stanley — Dow Jones Newswires, 13 November 2026 at 18:15 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗